August 2025 – Lacerta Bio

Video Discussion on GSK and Hengrui’s $12 Billion Agreement

Post author:Carlos
Post published:August 22, 2025
Post category:Business Development/Licensing China
Post comments:0 Comments

In July, 2025, GSK (UK) and Hengrui Pharmaceutical (China) executed a $12 billion license and option agreement valued at $12 billion, with $500 million paid upfront. The press release is…

Breaking Boundaries – How Geographically-Limited Pharmaceutical Companies Can Succeed in In-Licensing

Post author:Carlos
Post published:August 6, 2025
Post category:Business Development/Licensing Mergers & Acquisitions
Post comments:0 Comments

I. Introduction In our industry, not all companies are built for, or even aspire to, worldwide reach. Many are geographically limited, with commercial operations confined to a single country (such…

Get in touch